Pear has a long history with BioAge Labs and its co-founders, Kristen Fortney (CEO) and Eric Morgen (COO).

Pejman and Mar first met Kristen in 2015 through an introduction by another company founder associated with the Stanford Genome Technology Center. At that time, Kristen was a postdoc at Stanford in Professor Stuart Kim’s lab, where she studied the genetics of extreme human longevity. At the time, Kristen had published extensively in the space of genetics and longevity, but the company was merely an idea. She was pondering the question: could we use genetic information and new machine learning techniques to develop a therapy discovery platform for longevity? Kristen’s vision at the time was just as clear as it is today.

That year, Pear invested in BioAge’s initial seed financing, and we have gone on to successively back BioAge at every subsequent round, including the most recent Series D round.

We are incredibly excited to support BioAge Labs and optimistic about their future. We eagerly anticipate the results of its mid-stage clinical trials of azelaprag in obesity, as well as the development of additional programs nominated from its unique human aging target discovery platform.